Discontinued — last reported Q3 '22
Medtronic Acquisitions remained flat by 0.0% to $24.50M in Q1 2025 compared to the prior quarter. Year-over-year, this metric declined by 82.1%, from $137.00M to $24.50M. Over 3 years (FY 2022 to FY 2025), Acquisitions shows relatively stable performance with a 2.5% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $91.00M | $0.00 | $0.00 | $1.19B | $676.00M | $0.00 | $0.00 | $0.00 | $22.00M | $52.00M | $137.00M | $24.50M | $24.50M | $24.50M | $24.50M |
| QoQ Change | — | — | -100.0% | — | — | -43.2% | -100.0% | — | — | — | +136.4% | +163.5% | -82.1% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | — | +642.9% | — | — | -100.0% | -96.7% | — | — | — | +11.4% | -52.9% | -82.1% |